Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

DIVISLAB's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 6.943000
forwardPE 52.529686
debtToEquity 0.027000
earningsGrowth 0.231000
revenueGrowth 0.122000
grossMargins 0.602030
operatingMargins 0.301350
trailingEps 82.280000
forwardEps 56.300000

With a current ratio 6.943, DIVISLAB demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
DIVISLAB's high forward PE ratio indicates potential overvaluation, which could restrict future price growth and increase the risk of a correction. It's crucial to consider this metric in tandem with other fundamental data to fully assess the stock's outlook.
Divi's Laboratories Limited's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for Divi's Laboratories Limited.
DIVISLAB's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
Divi's Laboratories Limited's forward EPS being lower than its trailing EPS suggests that the company is expected to see a decline in profitability. This signals that the company may face a challenging financial year ahead.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

DIVISLAB's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in DIVISLAB's ability to achieve future growth.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


Divi's Laboratories Limited had 27 sell transactions, while the market price was at 5170.914849175348 per share.Divi's Laboratories Limited had 2 buy transactions while market price was at 5854.875 per share.The list of insider transactions is inconclusive, with no evident trend emerging to suggest a notable shift in company behavior or outlook.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


A recent buy bias from analysts toward DIVISLAB indicates strong confidence in the stock's future performance. This could encourage investors to park their money in DIVISLAB, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.